巨大細胞性動脈炎の世界市場レポート 2025年

巨大細胞性動脈炎の市場規模は、今後数年間で安定した成長が見込まれます。2029年には13億6,000万米ドルに成長し、CAGRは5.0%となります。予測期間の成長は、診断率の上昇、高齢化、ヘルスケア支出の増加、患者の支持、新しい地域への拡大などに起因します。予測期間における主な動向には、バイオマーカーの同定と検証の進展、特定の分子経路を標的とした治療法の開発、高度なイメージング技術の採用、ドラッグデリバリーの革新、予測分析のためのAIアルゴリズムの活用などがあります。

個別化医療への注目の高まりは、今後数年間の巨大細胞性動脈炎市場の成長を促進すると予想されます。個別化医療は、遺伝、ライフスタイル、環境要因などの個人の特性に合わせて治療を調整することを含みます。このアプローチは、ゲノミクス、バイオテクノロジー、データ分析の進歩により、治療効果を高め、患者の副作用を最小限に抑える、より正確な治療を可能にするため、勢いを増しています。巨大細胞性動脈炎（GCA）の文脈では、個別化医療は、遺伝的素因、免疫反応、特定の疾患症状などの要因に基づく標的療法につながります。例えば、2024年2月の個別化医療連合（PMC）によると、2023年に米国食品医薬品局（FDA）が承認した新薬の3分の1以上が個別化医薬品でした。これは4年連続の大幅な伸びを示し、2022年の6件の承認に対し、希少疾患向けに調整された16件の新たな治療が承認されました。これらの承認には、がんやその他の疾患に対する治療薬も含まれており、ヘルスケアにおける個別化アプローチの採用の増加と、GCAなどの疾患管理へのその影響が強調されています。

巨大細胞性動脈炎市場の主要企業は、治療の選択肢を広げ患者のニーズに応えるため、バイオシミラーなどの新製品を投入して前進しています。バイオシミラーとは、承認された生物学的製剤に極めて類似した生物学的製剤であり、安全性、純度、力価において臨床的に意味のある差がないことを保証するものです。例えば、2024年4月、Fresenius SE &Co.KGaAは、関節リウマチ（RA）、全身型若年性特発性関節炎（JIA）、多関節型若年性特発性関節炎（PJIA）、巨細胞性動脈炎を含む慢性自己免疫疾患に対して承認されたバイオシミラーであるTocilizumab-aazgを2024年4月に米国で発売しました。この承認は、薬物動態、安全性、免疫原性を参照トシリズマブ製剤と比較した第1相試験での包括的評価に基づくものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界巨大細胞性動脈炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の巨大細胞性動脈炎市場：成長率分析
• 世界の巨大細胞性動脈炎市場の実績：規模と成長, 2019-2024
• 世界の巨大細胞性動脈炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界巨大細胞性動脈炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の巨大細胞性動脈炎市場セラピューティクス社、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メトトレキサート
• トシリズマブ
• アスピリン
• 世界の巨大細胞性動脈炎市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫抑制剤
• 抗凝固薬
• その他の作用機序
• 世界の巨大細胞性動脈炎市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• その他の投与経路
• 世界の巨大細胞性動脈炎市場プレドニゾンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口プレドニゾン
• 静脈内（IV）プレドニゾン
• 低用量プレドニゾン療法
• 高用量プレドニゾン療法
• 世界の巨大細胞性動脈炎市場メトトレキサートのサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口メトトレキサート
• 皮下メトトレキサート
• メトトレキサート単剤療法
• メトトレキサート併用療法
• 世界の巨大細胞性動脈炎市場トシリズマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内トシリズマブ
• 皮下トシリズマブ
• トシリズマブ単剤療法
• トシリズマブとコルチコステロイドの併用
• 世界の巨大細胞性動脈炎市場アスピリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低用量アスピリン療法
• 心血管リスク管理のためのアスピリン
• アスピリン併用療法
• 腸溶性アスピリン

第7章 地域別・国別分析

• 世界の巨大細胞性動脈炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の巨大細胞性動脈炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 巨大細胞性動脈炎市場：競合情勢
• 巨大細胞性動脈炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi SA
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• CSL Limited
• Kiniksa Pharmaceuticals Ltd.
• MorphoSys AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 巨大細胞性動脈炎市場2029：新たな機会を提供する国
• 巨大細胞性動脈炎市場2029：新たな機会を提供するセグメント
• 巨大細胞性動脈炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Giant-cell arteritis (GCA) is a form of vasculitis, characterized by inflammation of medium to large arteries. It often affects the temporal arteries, causing symptoms such as headaches, scalp tenderness, and vision issues. If untreated, GCA can lead to severe complications such as blindness or stroke due to inflammation of vessel walls. Treatment typically involves high doses of corticosteroids to reduce inflammation and prevent complications.

Common therapeutics for giant-cell arteritis include prednisone, methotrexate, tocilizumab, and aspirin. Prednisone, a corticosteroid, works by suppressing inflammation and immune responses. It is administered via various routes such as oral, intravenous, and subcutaneous, and is utilized for its anti-inflammatory, immunosuppressive, and anticoagulant properties.

The giant-cell arteritis market research report is one of a series of new reports from The Business Research Company that provides giant-cell arteritis market statistics, including giant-cell arteritis industry global market size, regional shares, competitors with a giant-cell arteritis market share, detailed giant-cell arteritis market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. This giant-cell arteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The giant-cell arteritis market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to epidemiological studies, genetic insights, increasing adoption of biologics, improving diagnostic techniques, and development of targeted therapies and biologics.

The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing diagnosis rates, aging population, rising healthcare expenditure, patient advocacy, expansion into new geographic regions. Major trends in the forecast period include advancements in identifying and validating biomarkers, development of therapies targeting specific molecular pathways, adoption of advanced imaging techniques, drug delivery innovations, utilization of AI algorithms for predictive analytics.

The increasing focus on personalized medicine is expected to drive growth in the giant-cell arteritis market in the coming years. Personalized medicine involves tailoring medical treatments to individual characteristics such as genetics, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, biotechnology, and data analytics, which enable more precise therapies that enhance treatment effectiveness and minimize side effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can lead to targeted therapies based on factors such as genetic predispositions, immune responses, and specific disease symptoms. For example, according to the Personalized Medicine Coalition (PMC) in February 2024, over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023 were for personalized medicines. This marked the fourth consecutive year of significant growth, with 16 new treatments tailored for rare diseases approved, compared to six approvals in 2022. These approvals included medications for cancer and other conditions, underscoring the increasing adoption of personalized approaches in healthcare and their impact on disease management such as GCA.

Leading companies in the giant-cell arteritis market are advancing by introducing new products such as biosimilars to expand treatment options and meet patient needs. Biosimilars are biologic drugs highly similar to approved biological products, ensuring no clinically meaningful differences in safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA launched Tocilizumab-aazg in the U.S., a biosimilar approved for chronic autoimmune diseases including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval followed a comprehensive evaluation in a phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to reference tocilizumab products.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva's manufacturing facility in Goa, India, enhancing its production capacity significantly. This acquisition doubles Marksans Pharma's manufacturing capabilities in India, enabling the production of various pharmaceutical products including tablets, capsules, ointments, liquids, and creams. Teva Pharmaceutical, based in Israel, is known for its contributions in producing medications such as prednisone tablets used in the treatment of giant-cell arteritis.

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the giant-cell arteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Giant-Cell Arteritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on giant-cell arteritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for giant-cell arteritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The giant-cell arteritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin
• 2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action
• 3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration
• Subsegments:
• 1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy
• 2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy
• 3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids
• 4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Giant-Cell Arteritis Market Characteristics

3. Giant-Cell Arteritis Market Trends And Strategies

4. Giant-Cell Arteritis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Giant-Cell Arteritis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Giant-Cell Arteritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Giant-Cell Arteritis Market Growth Rate Analysis
• 5.4. Global Giant-Cell Arteritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Giant-Cell Arteritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Giant-Cell Arteritis Total Addressable Market (TAM)

6. Giant-Cell Arteritis Market Segmentation

• 6.1. Global Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methotrexate
• Tocilizumab
• Aspirin
• 6.2. Global Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Agents
• Anticoagulants
• Other Mechanisms Of Action
• 6.3. Global Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• Other Routes Of Administration
• 6.4. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Prednisone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Prednisone
• Intravenous (IV) Prednisone
• Low-Dose Prednisone Therapy
• High-Dose Prednisone Therapy
• 6.5. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Methotrexate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Methotrexate
• Subcutaneous Methotrexate
• Methotrexate Monotherapy
• Methotrexate Combination Therapy
• 6.6. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Tocilizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Tocilizumab
• Subcutaneous Tocilizumab
• Tocilizumab Monotherapy
• Tocilizumab In Combination With Corticosteroids
• 6.7. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Aspirin Therapy
• Aspirin For Cardiovascular Risk Management
• Aspirin In Combination Therapy
• Enteric-Coated Aspirin

7. Giant-Cell Arteritis Market Regional And Country Analysis

• 7.1. Global Giant-Cell Arteritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Giant-Cell Arteritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Giant-Cell Arteritis Market

• 8.1. Asia-Pacific Giant-Cell Arteritis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Giant-Cell Arteritis Market

• 9.1. China Giant-Cell Arteritis Market Overview
• 9.2. China Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Giant-Cell Arteritis Market

• 10.1. India Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Giant-Cell Arteritis Market

• 11.1. Japan Giant-Cell Arteritis Market Overview
• 11.2. Japan Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Giant-Cell Arteritis Market

• 12.1. Australia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Giant-Cell Arteritis Market

• 13.1. Indonesia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Giant-Cell Arteritis Market

• 14.1. South Korea Giant-Cell Arteritis Market Overview
• 14.2. South Korea Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Giant-Cell Arteritis Market

• 15.1. Western Europe Giant-Cell Arteritis Market Overview
• 15.2. Western Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Giant-Cell Arteritis Market

• 16.1. UK Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Giant-Cell Arteritis Market

• 17.1. Germany Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Giant-Cell Arteritis Market

• 18.1. France Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Giant-Cell Arteritis Market

• 19.1. Italy Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Giant-Cell Arteritis Market

• 20.1. Spain Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Giant-Cell Arteritis Market

• 21.1. Eastern Europe Giant-Cell Arteritis Market Overview
• 21.2. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Giant-Cell Arteritis Market

• 22.1. Russia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Giant-Cell Arteritis Market

• 23.1. North America Giant-Cell Arteritis Market Overview
• 23.2. North America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Giant-Cell Arteritis Market

• 24.1. USA Giant-Cell Arteritis Market Overview
• 24.2. USA Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Giant-Cell Arteritis Market

• 25.1. Canada Giant-Cell Arteritis Market Overview
• 25.2. Canada Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Giant-Cell Arteritis Market

• 26.1. South America Giant-Cell Arteritis Market Overview
• 26.2. South America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Giant-Cell Arteritis Market

• 27.1. Brazil Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Giant-Cell Arteritis Market

• 28.1. Middle East Giant-Cell Arteritis Market Overview
• 28.2. Middle East Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Giant-Cell Arteritis Market

• 29.1. Africa Giant-Cell Arteritis Market Overview
• 29.2. Africa Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Giant-Cell Arteritis Market Competitive Landscape And Company Profiles

• 30.1. Giant-Cell Arteritis Market Competitive Landscape
• 30.2. Giant-Cell Arteritis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Giant-Cell Arteritis Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb Company
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Boehringer Ingelheim
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. CSL Limited
• 31.14. Kiniksa Pharmaceuticals Ltd.
• 31.15. MorphoSys AG

32. Global Giant-Cell Arteritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Giant-Cell Arteritis Market

34. Recent Developments In The Giant-Cell Arteritis Market

35. Giant-Cell Arteritis Market High Potential Countries, Segments and Strategies

• 35.1 Giant-Cell Arteritis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Giant-Cell Arteritis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Giant-Cell Arteritis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer